Skip to content

A double blind, randomized, placebo-controlled trial for investigation of the intake of cranberry juice and cranberry juice-based powder on suppression of Helicobacter pylori in subjects currently infected with the bacteria

A double blind, randomized, placebo-controlled trial for investigation of the intake of cranberry juice and cranberry juice-based powder on suppression of Helicobacter pylori in subjects currently infected with the bacteria

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017522
Enrollment
Unknown
Registered
2018-08-02
Start date
2018-08-13
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H.pylori infection

Interventions

1 low-dose juice/day:1 low-dose juice/day
1 medium-dose juice/day:1 medium-dose juice/day
2 medium-dose juices/day:2 medium-dose juices/day
2 placebo medium-dose juices/day:2 placebo medium-dose juices/day
1 cranberry capsule/day:1 cranberry capsule/day
2 cranberry capsules/day:2 cranberry capsules/day
2 placebo capsules/day:2 placebo capsules/day

Sponsors

Peking University Cancer Hospital & Institute, Beijing Institute for Cancer Research
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Must test positive for Helicobacter pylori in urea breath test. (Ethical issues of recruiting H. pylori-positive subjects: relatively short study period not likely to be deleterious to health. Possibly offer cranberry non-responders antibiotic treatment at conclusion of the study): 1. Willingness to complete questionnaires, records, and diaries associated with the study and to complete all urea breath testing procedures; 2. Willingness to provide medical history, including family history of ulcers and stomach cancer; 3. Has given voluntary, written, informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Subjects diagnosed with an existing ulcer; 2. Subjects who are taking antibiotics currently or within the last 6 months for ulcers or other bacterial infections; 3. Subjects who have been treated for H. pylori with antibiotics; 4. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial; 5. Subject has a known allergy to the test materials active or inactive ingredients, as reported by subject; 6. Subjects with unstable or serious medical conditions, including stomach cancer; 7. Subjects taking blood thinners (Warfarin, Coumadin); 8. Alcohol or drug abuse within 6 months; 9. Individuals who are cognitively impaired and/or who are unable to give informed consent.

Design outcomes

Primary

MeasureTime frame
15% initial eradication rate;

Countries

China

Contacts

Public ContactKaifeng Pan

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing Institute for Cancer Research

pankaifeng2002@yahoo.com+86 010-88196937

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026